BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc.
WKN: 924801 / Symbol: BMRN / Name: BioMarin Pharmaceutical / Aktie / Pharmazeutika / Large Cap /
84,34 €
2,34 %
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $115.00 to $112.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Wells Fargo & Company from $110.00 to $115.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Stifel Nicolaus from $108.00 to $112.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Barclays PLC from $111.00 to $110.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at TD Cowen from $125.00 to $120.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. They now have a $110.00 price target on the stock, up previously from $94.00.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Stifel Nicolaus from $112.00 to $115.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
Neueste Beiträge
Stifel_Nicolaus in BioMarin Pharmaceutical Inc. diskutieren